Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Mar;28(3 Suppl):S19-25.
doi: 10.1097/IAE.0b013e318159ec6b.

Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity

Hugo Quiroz-Mercado  1 , Maria A Martinez-Castellanos, Myriam L Hernandez-Rojas, Nelida Salazar-Teran, Robinson Vernon Paul Chan
Affiliations

Antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity

Hugo Quiroz-Mercado et al. Retina. 2008 Mar.

Erratum in

  • Retina. 2009 Jan;29(1):127

Abstract

Purpose: To evaluate the role of antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity (ROP).

Methods: In this noncomparative, prospective, interventional case series, bevacizumab was injected into the vitreous of patients with ROP in three different groups: group I, patients with stage IVa or IVb ROP who had no response to conventional treatment; group II, patients with threshold ROP who were difficult to treat with conventional therapy because of poor visualization of the retina; and group III, patients with high-risk prethreshold or threshold ROP.

Results: Thirteen patients (18 eyes; mean age +/- SD, 4 +/- 3 months; mean follow-up, 6 months) were included in the study. We found neovascular regression in 17 eyes. One patient with stage IVa ROP had spontaneous retinal reattachment after an intravitreal injection of bevacizumab. There were no serious ocular or systemic adverse events.

Conclusion: The use of bevacizumab may be promising in the treatment of patients with ROP. Further studies need to be performed to determine the safety and long-term efficacy of intravitreal injection of bevacizumab, either as first-line therapy or after failure of conventional therapy.

PubMed Disclaimer

LinkOut - more resources